VU0452865 | 1392442-12-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: VU0452865
• 英文别名: [1-(5-Isoquinolinylsulfonyl)-3-azetidinyl][4-(4-pyridinyl)-1-piperazinyl]-methanone；(1-isoquinolin-5-ylsulfonylazetidin-3-yl)-(4-pyridin-4-ylpiperazin-1-yl)methanone
• CAS: 1392442-12-4
• 化学式: C₂₂H₂₃N₅O₃S
• 分子量: 437.522
• InChiKey: GOKSDAYTCVNLDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  95.1
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  异喹啉-5-磺酰氯 在 水 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 VU0452865
  参考文献：
  名称：

  Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012

  摘要：

  This Paper describes the continued optimization of an MLPCN probe molecule M-1 antagonist (ML012) through an iterative parallel synthesis approach. After several rounds of modifications of the parent compound, we arrived at a new azetidine scaffold that displayed improved potency while maintaining a desirable level of selectivity over other muscarinic receptor subtypes. Data for representative molecules 7w (VU0452865) and 12a (VU0455691) are presented. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.018

文献信息

• SUBSTITUTED (1-(METHYLSULFONYL)AZETIDIN-3-YL)(HETEROCYCLOALKYL)METHANONE ANALOGS AS ANTAGONISTS OF MUSCARINIC ACETYLCHOLINE M1 RECEPTORS
  申请人：Vanderbilt University

  公开号：US20130178458A1

  公开（公告）日：2013-07-11

  In one aspect, the invention relates to substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs, derivatives thereof, and related compounds, which are useful as antagonists of the muscarinic acetylcholine receptor M 1 (mAChR M 1 ); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
• Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012
  作者：Bruce J. Melancon、Thomas J. Utley、Christian Sevel、Margrith E. Mattmann、Yiu-Yin Cheung、Thomas M. Bridges、Ryan D. Morrison、Douglas J. Sheffler、Colleen M. Niswender、J. Scott Daniels、P. Jeffrey Conn、Craig W. Lindsley、Michael R. Wood

  DOI：10.1016/j.bmcl.2012.06.018

  日期：2012.8

  This Paper describes the continued optimization of an MLPCN probe molecule M-1 antagonist (ML012) through an iterative parallel synthesis approach. After several rounds of modifications of the parent compound, we arrived at a new azetidine scaffold that displayed improved potency while maintaining a desirable level of selectivity over other muscarinic receptor subtypes. Data for representative molecules 7w (VU0452865) and 12a (VU0455691) are presented. (c) 2012 Elsevier Ltd. All rights reserved.